Beam Therapeutics (BEAM) Earnings Analysis
Beam Therapeutics (BEAM) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -0.91 USD vs -0.87 USD est (-4.6%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -41.62.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BEAM next report earnings?
No confirmed upcoming earnings date is currently scheduled for BEAM. This page updates as the calendar is published.
BEAM earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.91 USD | -0.87 USD | -4.6% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
BEAM valuation and analyst view
| Trailing P/E | -41.62 |
|---|---|
| Trailing EPS | -0.62985 USD |
| Price / book | 2.36 |
| Dividend yield | 0.00% |
| Market cap | 2.75B |
| Analyst consensus | Buy (18 buy / 8 hold / 1 sell) |
| Avg price target | 59.5 USD |
Related research pages
Frequently asked questions
When is Beam Therapeutics (BEAM)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for BEAM. This page updates as the calendar is published.
Did BEAM beat earnings last quarter?
In its 2026-05-07 report, BEAM posted EPS of -0.91 USD versus a -0.87 USD estimate — a miss of 4.6%.
What is BEAM's earnings track record?
Over the last 1 reported quarters with consensus data, BEAM beat estimates 0 times (0%).
What is BEAM's current P/E ratio and EPS?
BEAM trades at a trailing P/E of -41.62 on trailing EPS of -0.6298541573860665 USD.
What do analysts rate BEAM?
Analyst consensus is "Buy" across 27 ratings (0 strong buy, 18 buy, 8 hold, 1 sell, 0 strong sell). Average 12-month price target: 59.5 USD.